Comments
Dear Sirs, Further to our letter dated 23rd May, 2019 and pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirement), Regulations 2015 we wish to inform you that the Board of Directors of the Company in its meeting held today, i.e. 30th May, 2019, have considered and approved the Audited standalone financial results for the quarter and financial year ended 31St March, 2019. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement), Regulations 2015, we enclose herewith: 1. Audited Standalone Financial Results for the quarter and year ended 31st March, 2019. 2. Independent Auditors Report on the Audited Financial Results for the quarter and year ended 31St March, 2019. 3. Statement on Impact of Audit Qualification on Standalone Financial results for the year ended March 31, 2019 in compliance with SEBI Circular No. ClR/CFD/CMD/56/2016 Dated May 27, 2016.
Pdf Link: Parmax Pharma Ltd - Results For Quarter And Financial Year Ended 31St March, 2019
Source : BSE - www.bseindia.com
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.